Clinical trials in Rotterdam – page 101

1 531 clinical trials in Rotterdam, The Netherlands across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Rotterdam at a glance

1 531

clinical trials

Research sites7

Quick filters

1 531 trials in Rotterdam

Open in trial search

Gastrooesophageal cancer+1

Not recruiting

Study of Retifanlimab, Capecitabine, and Oxaliplatin for First-Line Treatment in Patients with Metastatic Esophagogastric Cancer

InvestigationalNo placebo

Study of Retifanlimab, Capecitabine, and Oxaliplatin for First-Line Treatment in Patients with Metastatic Esophagogastric Cancer

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Retifanlimab
Sponsor:Amsterdam UMC Stichting

Contact Research Centre

Sickle cell anaemia+1

Not recruiting

Study on Crizanlizumab for Adolescents and Adults with Sickle Cell Disease Experiencing Vaso-Occlusive Crises

InvestigationalNo placebo

Study on Crizanlizumab for Adolescents and Adults with Sickle Cell Disease Experiencing Vaso-Occlusive Crises

InvestigationalNo placebo

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Substances:Crizanlizumab
Sponsor:Novartis Pharma AG

Contact Research Centre

Lung neoplasm malignant

Not recruiting

Study of Rilvegostomig (AZD2936) for Adults with Advanced or Metastatic Non-Small Cell Lung Cancer

InvestigationalNo placebo

Study of Rilvegostomig (AZD2936) for Adults with Advanced or Metastatic Non-Small Cell Lung Cancer

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Rilvegostomig
Sponsor:AstraZeneca AB

Contact Research Centre

Angina pectoris

Not recruiting

Study on the Effect of Diltiazem on Angina in Patients with Coronary Microvascular Dysfunction

Registered drug

Study on the Effect of Diltiazem on Angina in Patients with Coronary Microvascular Dysfunction

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Diltiazem Hydrochloride
Sponsor:Radboud universitair medisch centrum Stichting

Contact Research Centre

Acute myeloid leukaemia+2

Not recruiting

Study on the Safety and Effectiveness of Quizartinib for Children and Young Adults with Acute Myeloid Leukemia (AML)

InvestigationalNo placebo

Study on the Safety and Effectiveness of Quizartinib for Children and Young Adults with Acute Myeloid Leukemia (AML)

InvestigationalNo placebo

The Netherlands

Participants:0–17 years · 18–64 years
Substances:Quizartinib Dihydrochloride
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Bladder transitional cell carcinoma

Not recruiting

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Registered drugNo placebo

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Cetrelimab
Sponsor:Janssen Cilag International

Contact Research Centre

Follicle centre lymphoma follicular grade I II - III refractory

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Diffuse large B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Amyotrophic lateral sclerosis

Not recruiting

Study of utreloxastat (PTC857) in adults with Amyotrophic Lateral Sclerosis (ALS) to evaluate its effectiveness in slowing disease progression

Investigational

Study of utreloxastat (PTC857) in adults with Amyotrophic Lateral Sclerosis (ALS) to evaluate its effectiveness in slowing disease progression

Investigational

The Netherlands

Participants:18–64 years · 65+ years
Sponsor:PTC Therapeutics Inc.

Contact Research Centre

Prostate cancer

Not recruiting

Study of Pembrolizumab, Vibostolimab, and Belzutifan for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo

Study of Pembrolizumab, Vibostolimab, and Belzutifan for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Abiraterone
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Ovarian cancer stage IV+1

Not recruiting

Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

Registered drug

Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Dostarlimab
Sponsor:Tesaro Inc.

Contact Research Centre

Colorectal cancer

Not recruiting

Study for Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation Using Encorafenib, Cetuximab, and Chemotherapy Combination

Registered drugNo placebo

Study for Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation Using Encorafenib, Cetuximab, and Chemotherapy Combination

Registered drugNo placebo

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Pfizer Inc.

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Rotterdam

What the registry says about research in the country

01 Neurology and Mental Health

Innovative research focusing on frontotemporal dementia treatments and management of migraine in relation to obesity. Studies include evaluation of new therapeutic compounds and their effects on neurological conditions.

Dementia Treatment Studies
Migraine Management Research
Neurological Disease Interventions

Research aims to improve patient outcomes through targeted therapeutic approaches and innovative treatment methods.

02 Oncology and Cancer Research

Comprehensive studies targeting various forms of cancer, including advanced gastric cancer and bladder cancer. Research includes innovative imaging techniques and combination therapy approaches.

Gastric Cancer Treatment
Cancer Immunotherapy
Diagnostic Imaging Studies

Focus on developing more effective treatment strategies and improving diagnostic capabilities.

03 Metabolic and Endocrine Disorders

Clinical trials addressing obesity and related metabolic conditions, including innovative approaches to weight management and metabolic disease treatment. Studies evaluate new therapeutic options for thyroid disorders.

Weight Management Therapies
Thyroid Disease Treatment
Metabolic Disease Research

Research focuses on developing effective treatments for complex metabolic conditions.

Back to the Netherlands All countries